I-Mab Biopharma

I-Mab (NASDAQ: IMAB) is a U.S.-based, global biotech company

[I-Mab Biopharma @IMabBiopharma]

We are delighted to announce Dr. Xi-Yong (Sean) Fu as Interim CEO and Director of I-Mab. Dr. Fu brings a wealth of experience and leadership in the biotech industry, and we are confident that he will guide our talented team in continuing to advance our robust pipeline forward.

[I-Mab Biopharma @IMabBiopharma]

I-Mab will be presenting at the Jefferies Global Healthcare Conference on Wednesday, June 5th, 2024. Our management team will also be available for one-on-one and small group meetings throughout the day.

For more details and to access the webcast, visit: https://t.co/7FFaWtSz3c

[I-Mab Biopharma @IMabBiopharma]

I-Mab will be presenting at the 23rd Annual Needham Virtual Healthcare Conference on Thursday, April 11, 2024. Our management team will also be available for one-on-one and small group meetings throughout the day.

For more details: https://t.co/7aQX8HC0IW

[I-Mab Biopharma @IMabBiopharma]

We announced our financial results for the full year ended December 31, 2023. Please follow the link below to access the report.
https://t.co/DsAUw18fjj

[I-Mab Biopharma @IMabBiopharma]

Update: I-Mab plans to announce financial results for the full year ended December 31, 2023, and provide company updates on March 14, 2024, post-market at 5:00 p.m. EST.

[I-Mab Biopharma @IMabBiopharma]

Claudin 18.2 is emerging as a key therapeutic target for gastric cancer. Swipe below to see how our innovative bispecific antibody, Givastomig, stands out from other developing therapies.

[I-Mab Biopharma @IMabBiopharma]

Thank you for a productive dialogue at #JPM24.

View our latest presentation here: https://t.co/hSoERGuoSI

[I-Mab Biopharma @IMabBiopharma]

Hello 2024! We continue to advance our innovative pipeline forward with renewed vigor to deliver life-changing medicines to the people we serve.

Please stay tuned for more updates!

[I-Mab Biopharma @IMabBiopharma]

Reflecting on 2023's blessings and challenges, we head into 2024 with renewed hope and determination towards a healthier and happier future for all.

Wishing everyone a safe holiday season and a joyous, prosperous New Year!

[I-Mab Biopharma @IMabBiopharma]

I-Mab will attend the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco from January 8-11, 2024.

Our leaders look forward to connecting in person with investors and partners, discussing our latest progress and exploring future opportunities.

[I-Mab Biopharma @IMabBiopharma]

We invite you to visit https://t.co/oS0mC4SjsE

[I-Mab Biopharma @IMabBiopharma]

In this season of gratitude, we want to express our sincere thanks to those who have been a part of our journey to improve the lives of the people we serve.

[I-Mab Biopharma @IMabBiopharma]

Join I-Mab at the Piper Sandler 35th Annual Healthcare Conference. A fireside chat with CEO Mr. Raj Kannan and CMO Dr. John Hayslip is scheduled for 8:30 a.m. EST, on Nov 30th, 2023, where they will discuss the investment thesis, progress to date, and the strategic direction.

[I-Mab Biopharma @IMabBiopharma]

Stomach cancer often remains "silent" until it's advanced, which can be particularly lethal. This November, during Stomach Cancer Awareness Month, learn key facts about the disease, help raise awareness, and support advancements in research, diagnosis, and treatment.

[I-Mab Biopharma @IMabBiopharma]

I-Mab is pleased to present at the Jefferies London Healthcare Conference on November 14th at 10:30 a.m. GMT. Raj Kannan, CEO, and John Hayslip, CMO, will provide insights into our recent progress and strategic direction.

For more details: https://t.co/WsW6DXFBkC

[I-Mab Biopharma @IMabBiopharma]

Today, we announced that two poster presentations featuring preclinical data on Givastomig, our novel Claudin 18.2 x 4-1BB bispecific antibody, and TJ-L14B, our differentiated PD-L1 x 4-1BB bispecific antibody, will be reported at #SITC23.

For details: https://t.co/INQTDGbslX

[I-Mab Biopharma @IMabBiopharma]

We’re delighted to share that our poster on Givastomig, a novel Claudin 18.2 x 4-1BB bispecific antibody, received the Best Poster Award at the ESMO Congress 2023 for the October 23 poster session.

Congratulations to the authors and the entire team!

https://t.co/eMlrbLR7qh

[I-Mab Biopharma @IMabBiopharma]

Today, we're excited to present the encouraging Phase 1 data for Givastomig, our novel Claudin 18.2 x 4-1BB bispecific antibody, at #ESMO23.

Hear directly from our lead PI Dr. Geoffrey Ku and I-Mab CEO Mr. Raj Kannan as they share their insights.

Stay tuned for more updates!

[I-Mab Biopharma @IMabBiopharma]

Join I-Mab at #ESMO23 on October 23, 12:00 pm CET, where we will present Phase 1 clinical data of givastomig, our novel Claudin 18.2 x 4-1BB bispecific antibody.

We look forward to seeing you!

Learn more at: https://t.co/VW5FRyZYT4

[I-Mab Biopharma @IMabBiopharma]

We are excited to announce an important update on TJ-L14B/ABL503, a differentiated PD-L1 x 4-1BB bispecific antibody developed in collaboration with ABL Bio. This novel bispecific antibody aims to tackle tumors resistant to PD-(L)1 antibodies.

For details:https://t.co/pzzkKe9QkS